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Abstract
Background—The Bethesda assay (BA) for measurement of factor VIII (FVIII) inhibitors called 
for quantitation of positive inhibitors using dilutions producing 25–75% residual activity (RA), 
corresponding to 0.4–2.0 Bethesda units, recommending use of “more sensitive methods” for 
samples with RA closer to 100%. The Nijmegen modification (NBA) changed the reagents used 
but not these calculations. Some specimens negative by NBA have been shown to have FVIII 
antibodies detectable by sensitive immunologic methods.
Objective—To examine the performance at very low inhibitor titers of the Centers for Disease 
Control and Prevention (CDC)-modified NBA (CDC-NBA), which includes preanalytical heat 
inactivation to liberate bound anti-FVIII antibodies.
Methods—Specimens with known inhibitors were tested by CDC-NBA. IgG4 anti-FVIII 
antibodies were measured by fluorescence immunoassay (FLI).
Results—Diluted inhibitors showed linearity below 0.4 Nijmegen-Bethesda units (NBU). Using 
4 statistical methods, the limit of detection of the CDC-NBA was determined to be 0.2 NBU. IgG4 
anti-FVIII antibodies, which correlate most strongly with functional inhibitors, were present at 
rates above the background rate of healthy controls in specimens with titers ≥0.2 NBU and showed 
an increase in frequency from 14.3% at 0.4 NBU to 67% at the established threshold for positivity 
of 0.5 NBU.
Conclusions—The CDC-NBA can detect inhibitors down to 0.2 NBU. The FLI, which is more 
sensitive, demonstrates anti-FVIII IgG4 in some patients with negative (<0.5) NBU. The sharp 
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increase in IgG4 frequency between 0.4–0.5 NBU validates the established threshold for positivity 
of ≥0.5 NBU for the CDC-NBA, supporting the need for method-specific thresholds.
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Introduction
The “gold standard” assay for measurement of factor VIII (FVIII) inhibitors is the Nijmegen 
modification [1] of the Bethesda assay (BA) [2], according to International Society on 
Thrombosis and Haemostasis guidelines [3]. The Nijmegen-Bethesda assay (NBA) modified 
the reagents used in the BA but maintained its method of calculation of the inhibitor units 
based on a ratio of the FVIII activity in a mixture of patient plasma and normal pooled 
plasma (NPP) to the FVIII activity in a control mixture, expressed as the % residual activity 
(RA). The original description of the BA in 1975 [2] recommended that quantitation of 
positive inhibitors be carried out using %RA between 25% and 75%, corresponding to 0.4–
2.0 Bethesda units (BU), and, more recently, it has been suggested that the limit of detection 
of the BA is 0.4 NBU [4]. Although the graph provided by Kasper et al. (2) showed linearity 
to 100% RA, the authors recommended use of “more sensitive methods” for RA close to 
100%, an assertion that is supported by several more recent studies using sensitive 
immunologic methods to detect FVIII antibodies in specimens found to be negative by BA 
or NBA [5–10]. FVIII activity measurement methods have changed over the past 40 years, 
and documentation is lacking describing the performance of the BA and NBA at low titers 
using today’s automated methods to assign FVIII activity levels. The ability to accurately 
measure inhibitors in the 0–0.4 NBU range would allow for more precise monitoring of 
developing inhibitors. To this end, we have previously validated modifications to the NBA to 
free anti-FVIII antibodies bound to FVIII and increase its precision [12] in order to 
minimize the number of false negative results, and assay modifications to increase the 
sensitivity of the NBA have been proposed for use in monitoring of immune tolerance 
induction therapy (ITI) [11]. In this report, we examined the performance of the CDC-
modified Nijmegen-Bethesda assay (CDC-NBA) at very low inhibitor titers in a single 
laboratory and used measurement of anti-FVIII antibodies to validate the limit of detection 
and threshold for positivity established.
Materials and Methods
Specimens for FVIII inhibitor testing were collected from subjects with congenital 
hemophilia A enrolled in the Hemophilia Inhibitor Research Study between 2006–2012 at 
17 U.S. Hemophilia Treatment Centers, as described in detail elsewhere [12, 13]. Healthy 
control subjects were paid donors with no history of coagulation disorder.
FVIII inhibitor measurements were performed by the CDC-NBA, as previously described 
[12]. Specimens were tested undiluted and at serial two-fold dilutions of 0.5, 0.25, 0.125, 
etc., in FVIII-deficient plasma (FVIIIDP, George King Biomedical, Overland Park, KS) until 
a dilution with 100% RA was reached. Antibodies of IgG4 subclass binding to FVIII were 
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measured by fluorescence immunoassay (FLI) as previously described [9], in 382 
specimens. The threshold for positivity for IgG4 antibodies was set at 2 standard deviations 
above the mean for 56 healthy subjects [9].
Dilution curves were evaluated by linear regression with significance of deviation from 0 
slope calculated by F test and linearity by runs test with a significance level of P<0.5. Limit 
of detection (LOD) of the assay was estimated by four methods. Method 1: using the 
classical method as described by the Clinical and Laboratory Standards Institute (CLSI) 
[14], 4 blank specimens prepared from equal parts normal pooled plasma (NPP) and 
FVIIIDP and 4 low level specimens of 1.0 NBU prepared by diluting high-titer inhibitor 
plasma (George King) in imidazole buffer (Siemens, Marburg, Germany) were tested using 
2 different lots of assay reagents over 3 days with a total of 60 replicates of each type of 
specimen. Non-parametric methods were used to calculate limit of the blank (LOB) as the 
95th percentile rank for negative specimens. LOD was calculated as the LOB plus the 
standard deviation (SD) of the low level specimens corrected to the 95th percentile of the 
normal distribution. Method 2: the lowest dilution detected, i.e., having less than 100% RA 
(> 0 NBU), was calculated for 17 FVIII inhibitors of 1.0–24.6 NBU. Method 3: linear 
regression of the lower dilutions of 14 positive inhibitors with at least 3 dilutions between 
50% and 100% RA: 1.1–1.7 NBU (n=5), 6.7–9.6 NBU (n=4), 13.1–14.9 NBU (n=3), and 
23.0–24.6 NBU (n=2), was performed. Mean and SD of the NBU at which the regression 
line reached 100% RA and slope were calculated, and the LOD was calculated as 3SD/
slope. Method 4: specimens from 30 healthy subjects were tested and LOD was calculated 
as mean + 3SD. Analyses were performed using GraphPad Prism 6.0 (GraphPad Software 
Inc., San Diego, CA).
Results and Discussion
The CDC-NBA has been previously shown to have a coefficient of variation (CV) between 
runs for the negative control of 9.8% (n = 117) and for the 1.0 NBU positive control of 
10.3% (n=114). Within-runs variation showed a CV of the negative control of 5.3% (n = 10) 
and of the positive control 4.8% (n = 10) [12]. The CDC-NBA was performed on serial 
dilutions of high (13.1–24.6 Nijmegen-Bethesda units (NBU); Figure 1A), low (1.1–1.7 
NBU; Figure 1B), and very low/negative (0.6 and 0.8 NBU/<0.5 NBU; Figure 1C) 
specimens in order to assess the assay’s ability to measure inhibitors in specimens 
containing inhibitors approaching 100% RA. Linearity of each curve was verified by a runs 
test. All positive specimens showed linearity with a significant negative slope. Linearity 
between 100% and 75% RA suggests that NBU can be read below 0.4 NBU; however, the 
curves did not cross the y-axis at 100% RA, indicating that the LOD of this assay is not 0 
NBU. As shown in Figure 1C, very low positive specimens (0.6 and 0.8 NBU) showed a 
similar change with dilution, while negative specimens showed a consistent %RA when 
diluted and lacked a negative slope. Observation of multiple dilutions, even when not 
required by the assay protocol, may be useful in distinguishing very low titer inhibitors from 
negative specimens.
Calculation of LOD, the lowest level at which inhibitor can be detected, by 4 standard 
methods is shown in the Table. All four statistical methods used indicate that the lower limit 
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of detection of the CDC-NBA, which is reported to one decimal place, is 0.2 NBU. Similar 
calculations can be carried out by clinical laboratories using specimens prepared from 
assayed plasmas obtained commercially or from laboratories using validated methods.
Dardikh et al developed a modified NBA which utilizes concentrated plasma in a 
chromogenic assay with a reported sensitivity of 0.03 NBU and reported that it detects low 
titer inhibitors that remain after ITI and are responsible for reduced FVIII half-life [11]. 
Such an assay may be superior to the NBA for this purpose; however, further studies using 
the FLI, which has a similar sensitivity [16], for ITI monitoring are warranted.
A threshold for positivity of ≥0.5 NBU for the CDC-NBA was previously established based 
on patient history in 674 subjects [12]; its range can be estimated based on the CV of the 
CDC-NBA to be 0.45–0.55. Because functional inhibitor titers have been shown to correlate 
most strongly with levels of anti-FVIII antibodies of IgG4 subclass [8, 9, 17–19], we 
measured anti-FVIII IgG4 in specimens at various inhibitor titers (Figure 2). Among 64 
specimens with ≥2.0 NBU, 62 (97%) demonstrated the presence of anti-FVIII IgG4. Those 
with titers of 0.6–1.9 NBU had frequencies of 79–83%. At the CDC-NBA cutoff for 
positivity of 0.5 NBU, IgG4 frequency was 66.7%, decreasing to 14.3% at 0.4 NBU. IgG4 
antibodies were present in specimens with titers ≥0.2 NBU at rates above that seen in 
healthy controls [9]. These data confirm that a majority of specimens become antibody-
positive at 0.5 NBU. Figure 2 also illustrates that specimens with 0.5–1.9 NBU have a lower 
frequency of IgG4 positivity than higher titer specimens, confirming the false positive rate in 
that range previously reported with assays detecting both IgG and IgM antibodies [16]. IgG4 
anti-FVIII antibodies were absent in 19% of specimens with 0.5–1.9 NBU.
The presence of IgG4 anti-FVIII antibodies in some specimens below the positive threshold 
confirms previous observations [5–10] that some patients with a negative NBA have 
developed an antibody response to FVIII. In some cases, these antibodies appear to have 
clinical effects [7, 10]. A 9-year-old HA patient with titers of 0.4 NBU and 0.4 chromogenic 
Bethesda units and strongly positive anti-FVIII antibodies was observed to have FVIII 
recovery of 10% of expected and half-life of 2 hours post infusion. ITI therapy increased his 
recovery to 80% and his half-life to 6 hours [unpublished observation]. These observations 
and the finding that patients with titers of 0.5–1.9 NBU and those with higher titers have 
similar levels of anti-FVIII antibodies by FLI [20] suggest that in vitro measurement of 
inhibition may not always reflect the antibody load. In vitro conditions may not accurately 
mimic those present in vivo, where antibody affinity may play a role in determining the 
effect [21]. Diagnosis of an inhibitor in a hemophilia patient is a clinical judgement and 
should not be included or excluded solely on the basis of a threshold for positivity.
These results document that the threshold of positivity with the CDC-NBA is slightly 
different from previous recommendations [3] based on the NBA without preanalytical heat 
inactivation, suggesting the need to re-evaluate the threshold for positivity when significant 
changes are made to the method. The FLI or other immunologic test may be useful as an 
objective measure for setting the threshold for a particular method. It has not been standard 
practice for each laboratory to set a reference range for FVIII inhibitors, and most 
laboratories lack sufficient specimens to do so. In order to use published definitions, 
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however, published methods must be carefully followed with any changes in procedure or 
substitution of reagents validated.
The CDC-NBA produces acceptable intra-laboratory variability using the positive and 
negative controls recommended, which can be prepared from commercially-available 
reagents [12]. Inter-laboratory variability was not examined in this study. Inter-laboratory 
variability of FVIII inhibitor results in external quality assessment programs is large, with 
CVs approaching 50% on distributed specimens and false-positive rates up to 32% [4, 22, 
23]. This has been attributed to differences in laboratory methods and reagents. A study with 
13 participants showed that a mean CV of 44% for 6 specimens using their original methods 
could be reduced to 8% by use of a standardized Nijmegen method and uniform reagents 
[23], suggesting that adoption of a standard method on a national or international level and 
use of validated reagents could lead to improvement. Standardization has been limited by the 
lack of commercial availability of key reagents, such as imidazole-buffered NPP and 
controls, cost of FVIII-deficient plasma, and lack of an international standard.
Introduction of new longer-acting treatment products has resulted in factor measurement 
issues, with differences noted based on the specific assay reagents used [24]. Inhibitor assays 
using preanalytical heat inactivation avoid this issue, because the calculated NBU is based 
on a ratio of two FVIII activity readings measuring the FVIII activity of the added NPP and 
not patient or infused FVIII, which has been removed. If the two FVIII measurements used 
to calculate an inhibitor are then carried out with appropriate quality control using 
calibrators allowing reporting in international units, theoretically, differences in factor assay 
reagents and instruments should not affect the final NBU. This, however, remains to be 
demonstrated. Accuracy of the test will be dependent upon the ability of the preanalytical 
heat inactivation step to remove any treatment product that may influence the results of the 
FVIII assays. This remains to be established with most significantly modified treatment 
products.
In conclusion, the CDC-NBA can detect inhibitors down to 0.2 NBU. The FLI, which is 
more sensitive, demonstrates anti-FVIII IgG4 in some patients with negative (<0.5) NBU. 
The sharp increase in IgG4 frequency between 0.4–0.5 NBU validates the established 
threshold for positivity of ≥0.5 NBU for the CDC-NBA. Further evaluation of the CDC-
NBA in a multi-laboratory study is warranted.
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Essentials
• Immunologic methods detect factor VIII (FVIII) antibodies in some inhibitor-
negative specimens.
• Specimens were tested by modified Nijmegen-Bethesda assay (NBA) and 
fluorescence immunoassay.
• The NBA with preanalytical heat inactivation detects FVIII inhibitors down to 
0.2 NBU.
• IgG4 frequency validates the established threshold for positivity of ≥0.5 NBU 
for this NBA.
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Figure 1. 
Dilution curves of factor VIII inhibitors measured by the CDC Nijmegen-Bethesda assay. A. 
Inhibitors of 13.1–24.6 Nijmegen-Bethesda units (NBU). B. Inhibitors of 1.1–1.3 NBU. C. 
Positive inhibitors of 0.6 and 0.8 NBU and negative inhibitors (<0.5 NBU).
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Figure 2. 
Per cent (%) of hemophilia A specimens positive for anti-factor VIII IgG4 antibodies at 
various levels of inhibitor measured in Nijmegen-Bethesda units by the CDC Nijmegen-
Bethesda assay
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Table
Calculation of the limit of detection (LOD) of the CDC-modified Nijmegen-Bethesda method for factor VIII 
inhibitors in Nijmegen-Bethesda units (NBU)
METHOD SAMPLES MEAN (RANGE) LOD NBU
CLASSICAL METHOD (CLSI)14 4 blank, 4 low -- 0.18
LOWEST DILUTION DETECTED15 17 (1–24 NBU) 0.19 (0.14–0.25) 0.19
LINEAR REGRESSION15 14 (1–24 NBU) 0.06 (0.01–0.14) 0.24
NEGATIVE SPECIMENS15 30 healthy subjects 0.03 (0–0.15)
SD 0.047
0.17
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